Ixico to extend work on Huntington's disease trial

Neuroimaging-focussed contract research organisation Ixico announced on Tuesday that an existing client has asked it to extend its breadth of services on their phase 1 and 2 trial into Huntington’s disease.

The AIM-traded firm originally announced its work on the trial in April 2019.

It said the request would result in a contract extension worth around £0.8m, which it expected to deliver across four years.

“Huntington’s disease is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities,” the board explained in its statement.

At 0800 BST, shares in Ixico were down 2.67% at 36.5p.

Reporting by Josh White at Sharecast.com.